TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04518943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.
Study: NCT05931965

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-methylfolate
Description: Participants receive L-methylfolate 400µg orally twice daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Participants receive mecobalamin 500µg intramuscularly stat on alternate days (6 total injections)
Study: NCT04957095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine Injectable Solution
Description: Apomorphine injected for therapeutic relief

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subcortical Stimulation
Description: Subcortical simulation of the deep brain stimulation surgery target site will be applied by clinically placed deep brain stimulation electrodes at the previously determined therapeutic setting
Study: NCT05303272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Prefilled Syringe
Description: Abatacept (Orencia) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product. Combined with standard of care prednisone 10-40mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil 500Mg Tab
Description: MMF will be administered at a starting dose of 1000 milligrams (mg) Q12H and the dose will be tapered to achieve a goal of 0.5-1.0 gram (gm) Q12H. Combined with standard of care prednisone 10-40mg qd through 52 weeks.
Study: NCT06532552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VACl Alternating With VACh
Description: VACl:~Azacitidine:75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100 mg d1, 200mg d2, 400mg d3-28) Cladribine: 5mg/m2 IV over approximately 1 to 2 hours, daily on days 1-3.~VACh:~Azacitidine: 75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28) Chidamide: 10mg orally daily for 12 days
Study: NCT05931965

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: magnesium
Description: Participants receive magnesium glycinate 400mg twice daily orally for 4 weeks (elemental 120mg approx.)
Study: NCT04775758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-evaluating questionnaires
Description: Patients are asked to describe their disease (gathering of anamnesis) and to categorize their symptoms according to their strength. Furthermore, patients complete self-evaluating questionnaires: Visual analog scale, Hospital anxiety and depression scale, Pittsburgh sleep quality index, Big five personality traits questionnaire.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-evaluating questionnaires
Description: Patients are asked to describe their disease (gathering of anamnesis) and to categorize their symptoms according to their strength. Furthermore, patients complete self-evaluating questionnaires: Visual analog scale, Hospital anxiety and depression scale, Pittsburgh sleep quality index, Big five personality traits questionnaire.
Study: NCT06532552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VA
Description: Azacitidine: 75mg/m2 Subcutaneous (SC) daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28).
Study: NCT05062460

Intervention type: OTHER
Group type: OTHER
Intervention: 1 hour Blood glucose monitoring
Description: Consented patients who are diagnosed with gestational diabetes will be randomized to 1-hour postprandial blood glucose monitoring.

Intervention type: OTHER
Group type: OTHER
Intervention: 2 hour blood glucose monitoring
Description: Consented patients who are diagnosed with gestational diabetes will be randomized to 2 hour post prandial blood glucose monitoring
Study: NCT05772559

Intervention type: OTHER
Intervention: Collection of blood sample of bone marrow (cohort 1)
Description: * 3 additional tubes of blood sample (cohort 1), at diagnosis and upon relapse if relapse occurs~* Bone marrow aspirate : 3 additional tubes (cohort 1), at diagnosis and upon relapse if relapse occurs

Intervention type: OTHER
Intervention: Collection of blood sample of bone marrow (cohort 2 and 3)
Description: * 1 additional tube of blood sample (cohort 2 and 3 at inclusion)~* Bone marrow aspirate: 1 additional tube (cohort 2 and 3 at inclusion)
Study: NCT04775758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMotions analysis platform
Description: While patients' anamnesis and questionnaire indexes are being gathered, iMotions software will gather facial expression analysis, galvanic skin response and heart rate data which will be compared with self-evaluating questionnaires.
Study: NCT05979129

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: zero PEEP
Description: zero end-expiratory pressure during face mask ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low PEEP
Description: 4 cmH2O PEEP during mask ventilation
Study: NCT04775758

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iMotions analysis platform
Description: While patients' anamnesis and questionnaire indexes are being gathered, iMotions software will gather facial expression analysis, galvanic skin response and heart rate data which will be compared with self-evaluating questionnaires.
Study: NCT05979129

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high PEEP
Description: 8 cmH2O PEEP during mask ventilation
Study: NCT05772559

Intervention type: OTHER
Intervention: Collection of blood sample of bone marrow (cohort 2 and 3)
Description: * 1 additional tube of blood sample (cohort 2 and 3 at inclusion)~* Bone marrow aspirate: 1 additional tube (cohort 2 and 3 at inclusion)
Study: NCT06242496

Intervention type: OTHER
Intervention: Retrospective follow-up
Description: Data collection
Study: NCT06342297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermatoscopy
Description: Dermatoscopy used in decision of surgical margin before resection of basal cell carcinoma or cutaneous squamous cell carcinoma
Study: NCT06258993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Exercise Promotion Program
Description: Core intervention content will be delivered during the Visit 1 and 1-Month-Check-in meetings. Definitions of exercise will be provided, participants will be asked to discuss their past experiences with exercise, guidelines for being safe during exercise will be reviewed, and strategies for overcoming potential barriers to exercise will be discussed. All participants will be given an exercise plan organized according to the FIIT Principle (Frequency, Intensity, Time, and Type). The intensity component of the exercise plan will differ by study arm, all other elements will be delivered the same across both conditions. All participants will be given the goal of increasing weekly time spent exercising to ≥150 minutes, consistent with recommended guidelines. All participants will be given a smartwatch to support self-monitoring of exercise and activity levels throughout the 12-week study period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Core Exercise Promotion Program
Description: Core intervention content will be delivered during the Visit 1 and 1-Month-Check-in meetings. Definitions of exercise will be provided, participants will be asked to discuss their past experiences with exercise, guidelines for being safe during exercise will be reviewed, and strategies for overcoming potential barriers to exercise will be discussed. All participants will be given an exercise plan organized according to the FIIT Principle (Frequency, Intensity, Time, and Type). The intensity component of the exercise plan will differ by study arm, all other elements will be delivered the same across both conditions. All participants will be given the goal of increasing weekly time spent exercising to ≥150 minutes, consistent with recommended guidelines. All participants will be given a smartwatch to support self-monitoring of exercise and activity levels throughout the 12-week study period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect-based exercise prescription
Description: Participants assigned to Affect-Rx will receive instructions to select a pace of exercise that makes you feel as good as possible. The exercise intensity prescription section of their exercise plan will include the Feeling Scale as an attachment and participants will be given the instruction to stay in the green zone on the Feeling Scale.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effort-based exercise prescription
Description: Participants assigned to RPE-Rx will receive instructions to select a pace that would make it challenging for you to carry on more than a short conversation. The exercise intensity prescription section of their exercise plan will include the Rating of Perceived Exertion (RPE) scale as an attachment and participants will be given the instruction to stay in the green zone on the RPE Scale.
Study: NCT04911114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be-Balanced
Description: The BE-BALANCED program will run for 12-weeks, with participants attending group-based virtual supervised exercise sessions twice weekly. Participants will complete an individual in-person assessment at baseline and again at end of intervention to collect physical outcome measures and will complete questionnaires electronically using REDCap, (or mailed version). Follow-up assessments will be administered electronically to each participant using REDCap at 3-months after program completion (24 weeks post-baseline).
Study: NCT04577820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: garetosmab
Description: Repeated doses administered intravenously (IV) every four weeks (Q4W)
Study: NCT06217718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telenursing Interventions
Description: Patient follow-up with phone calls and text messages
Study: NCT05484258

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Medical Visit
Description: Group visit wherein physician and Social Worker, would be discussing topics relevant to the population.
Study: NCT04734756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dragonfly Transcatheter Mitral Valve Repair System
Description: To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
Study: NCT05126823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy + app
Description: In the group ACT+app, experiential exercises are carried out, metaphors, discussions and assignments are used to promote awareness and flexibility about the thoughts and emotions associated with cancer and interleaved non-contact activities, which will serve as support for each of the modules. The non-contact activities will consist of assigning tasks, practices (mindfulness, breathing), reminder systems, recording, reinforcement and monitoring. Resources such as short texts, videos, audio files and recording systems will be used

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and commitment therapy
Description: In the group ACT, experiential exercises are carried out, metaphors, discussions and assignments are used to promote awareness and flexibility about the thoughts and emotions associated with cancer
Study: NCT06440304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin
Description: Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eravacycline
Description: Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ampicillin/sulbactam
Description: Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
Study: NCT04770168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Curriculum
Description: The 3-month Harry Potter curriculum is delivered by trained teachers and includes lessons on a) risk factors that can contribute to emotional distress, b) how depression and anxiety manifest and how to access support/treatment, c) cognitive distortions, how they differ from rational thoughts and basic cognitive restructuring techniques, d) crisis planning including personalized stressbusters and hope kits, and e) how to be resilient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Curriculum
Description: The 3-month Harry Potter curriculum is delivered by trained teachers and includes lessons on a) risk factors that can contribute to emotional distress, b) how depression and anxiety manifest and how to access support/treatment, c) cognitive distortions, how they differ from rational thoughts and basic cognitive restructuring techniques, d) crisis planning including personalized stressbusters and hope kits, and e) how to be resilient.
Study: NCT05727566

Intervention type: OTHER
Intervention: visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency
Description: visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency

Intervention type: OTHER
Intervention: visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency
Description: visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency
Study: NCT06483100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elrantamab
Description: - Elranatamab will be dosed in 28-day cycles as follows:~* C1D1: 12 mg SC priming dose~* C1D4: 32 mg SC priming dose~* C1D8, C1D15, C1D22: 76 mg SC~* Cycle 2 and all subsequent cycles: 76 mg SC on D1 and D15

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clonoSEQ
Description: FDA approved MRD testing
Study: NCT05433103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Load Exercise with Blood Flow Restriction
Description: Participants in the BFR group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training with at least 60% blood flow occlusion. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
Study: NCT05527314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Anesthesia was induced with Remimazolam 0.4-0.8 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h until the end of surgery.
Study: NCT05433103

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-Load Exercise Control Group
Description: Participants in the Control group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
Study: NCT05527314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia was induced with 8 % Sevoflorane by sevoflurane volatilization tank until the loss of consciousness (LoC), followed by 2 %-3 % Sevoflorane until the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.
Study: NCT05980052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Theory-driven behavioral physical activity promotion intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Theory-driven behavioral physical activity promotion intervention.
Study: NCT05527314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium Besylate
Description: Anesthesia was induced with cisatracurium besilate 0.1 mg/kg by intravenous injection after the LoC. And the cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate during the operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium Besylate
Description: Anesthesia was induced with cisatracurium besilate 0.1 mg/kg by intravenous injection after the LoC. And the cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate during the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
Study: NCT06265649

Intervention type: OTHER
Intervention: NOM
Description: Non-operative management (NOM) for ALCD consists of lab test monitoring, fluid therapy, antibiotic therapy, abscess drainage if \>4cm, restoring a regular diet
Study: NCT06162676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV game
Description: A brief health game for parent-child dyads to promote child's HPV vaccination
Study: NCT06336824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid
Description: The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
Description: The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group.
Study: NCT05090410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgotinib 200mg/day
Description: Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous tocilizumab 162mg/biweekly
Description: Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
Study: NCT05634590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: 4mg, orally, once daily, 3 weeks on/ 1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Oxaliplatin 85 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
Study: NCT05524272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: This study aims to evaluate the effects of colour by number mandala in decreasing the stress of children hospitalized due to their chronic disease.
Description: Colour by number Mandala in different sizes includes pictures and numbers. The child has to find the colour specified in the number and colour it with the specified colour. Colourful pictures emerge as a result of colouring